• Login
    View Item 
    •   Home
    • UA Graduate and Undergraduate Research
    • UA Theses and Dissertations
    • Dissertations
    • View Item
    •   Home
    • UA Graduate and Undergraduate Research
    • UA Theses and Dissertations
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UA Campus RepositoryCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournalThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournal

    My Account

    LoginRegister

    About

    AboutUA Faculty PublicationsUA DissertationsUA Master's ThesesUA Honors ThesesUA PressUA YearbooksUA CatalogsUA Libraries

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Identification and Development of Novel TRKA, FLT3, and Dual Aurora B/CSF-1R Kinase Inhibitors

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    azu_etd_16200_sip1_m.pdf
    Size:
    15.70Mb
    Format:
    PDF
    Download
    Author
    McConnell, Nicholas
    Issue Date
    2018
    Advisor
    Wondrak, Georg
    
    Metadata
    Show full item record
    Publisher
    The University of Arizona.
    Rights
    Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
    Embargo
    Release after 30-Mar-2021
    Abstract
    Kinase inhibitors have been one of the most widely studied drug classes over the last 30 years. Due to their extensive roles in nearly all biological processes and implications in tumorigenesis and progression, kinases have become one of the flagships of targeted therapy. Impressive efforts in drug development have led to FDA approval for 39 small molecule kinase inhibitors with many more in clinical trials. Although extensive work has already been completed, there is still room for progress. Many kinases that have been identified as drivers for malignant disease are yet to have any treatment approved for therapeutic use. Further, the biological significance and therapeutic value of multiple emerging targets is still being uncovered. The rise of kinase inhibitors in targeted therapy has also brought on challenges with resistance and relapse in patients. These obstacles have created a demand for developing kinases capable of broad mutant activity as well as revealed opportunities in polypharmacology to strategically target multiple targets to minimize risks of resistance. The work presented here describes the effort towards developing inhibitors for four currently underserved kinase targets: tropomyosin receptor kinase A (TRKA), FMS-like tyrosine kinase 3 (FLT3), Aurora B, and colony stimulating factor 1 receptor (CSF-1R). TrkA kinase is a long sought therapeutic target for both cancer and pain that is yet to have an inhibitor obtain FDA approval. 2017 saw the first approval of a FLT3 inhibitor, midostaurin, however it was not fully optimized for FLT3 activity. Inhibitors capable of maintaining full efficacy across FLT3 drug resistant mutants are still needed. Aurora B is another well studied kinase that lacks approved treatment, and CSF-1R is an emerging immunotherapy target aimed at stimulating anti-tumor macrophage activity. Combined, these two targets are optimal candidates for the development of polypharmacological studies. Heavy emphasis was placed on expediting the drug discovery process for identifying novel inhibitors of these kinase targets. Utilization of computational modeling techniques, kinase directed compound libraries, and efficiency enabling synthetic methodologies sought to progress compounds through the drug discovery pipeline as rapidly as possible. In total, the thesis project herein seeks to identify opportunities to provide improved treatment options and future directions for the field of kinase inhibitor development.
    Type
    text
    Electronic Dissertation
    Degree Name
    Ph.D.
    Degree Level
    doctoral
    Degree Program
    Graduate College
    Pharmaceutical Sciences
    Degree Grantor
    University of Arizona
    Collections
    Dissertations

    entitlement

     
    The University of Arizona Libraries | 1510 E. University Blvd. | Tucson, AZ 85721-0055
    Tel 520-621-6442 | repository@u.library.arizona.edu
    DSpace software copyright © 2002-2017  DuraSpace
    Quick Guide | Contact Us | Send Feedback
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.